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Figure 1. Multi-modality imaging from a representative LN patient. Left: Map of the initial
rate of enhancement (DYNAMIKA™) from DCE-MRI showing the degree of perfusion (the
white-yellow colors correspond to increased and the redder colors decreased perfusion) in
which decreased perfusion can be seen in the anterior pole of the right kidney (arrow); Left
center: DWI sequence that shows diffusion; Right center: T1rho illustrating fibrosis; and
Right:T2*Map/BOLD to investigate tissue oxygenation within the renal medullary tissue.
Conclusion: The initial assessment of 5 LN subjects has established the
feasibility of multi-modality imaging as a tool to evaluate LN in a multi-
center study. By assessing functional and structural MRI outcomes and
correlating them to clinical data, this study will provide essential prelimi-
nary evidence on the value of multi-modality imaging in diagnosis and
evaluating the response to treatment of LN patients.
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Background: Fatigue is the most prevalent symptom in Systemic Lupus
Erythematosus (SLE) as it is present in up to 90% of patients; it is con-
sidered to be the most disabling symptom in around half of the patients
[1,2]. Its aetiology is multi-factorial and there is conflicting evidence on
the relationship between fatigue and SLE disease activity, and between
fatigue and vitamin D deficiency. The Ad Hoc Committee on Systemic
Lupus Erythematosus Response Criteria for Fatigue recommended the
Fatigue Severity Scale (FSS) for the measurement of fatigue in SLE
[2,3].
Objectives: The aim of the study was to characterise the relationship
between fatigue and other factors, including disease activity, vitamin D
level, pain, depression, anxiety, sleep quality and exercise in SLE. More-
over the prevalence of fatigue in the Maltese population of SLE patients
was established.
Methods: 92 SLE patients, who fulfilled the SLICC classification criteria
for SLE, gave informed consent to participate in the study. This consisted
of an interview, blood and urine tests, and filling the questionnaires:
Fatigue Severity Scale (FSS), visual analogue scale (VAS) for fatigue,
Hospital Anxiety and Depression Scale (HADS), VAS for pain, Pittsburgh
Sleep Quality Index (PSQI) and modified Health Assessment Question-
naire (mHAQ). SLE disease activity was measured by SLE disease activ-
ity index-2K (SLEDAI-2K). Approval to carry out this study was obtained
from the University Research Ethics Committee.
Results: The mean age of the cohort studied was 46.9 years. 92.4%
were females and the median disease duration was 13 years. 56.5% had
an abnormal level of fatigue (FSS >3.7) and the median FSS was 4.17.
Fatigue measured by FSS, had a significant correlation with VAS Pain
(R=0.536, p<0.001), HADS-D (R=0.535, p<0.001), HADS-A (R=0.395,
p<0.001), PSQI (R=0.551, p<0.001) and mHAQ (R=0.435, p<0.001). VAS
fatigue had a significant correlation with SLEDAI-2K (R=0.247, p=0.018).
There was no significant relationship between fatigue and vitamin D level
or regular exercise. ANCOVA analysis showed that fatigue measured by
FSS and VAS fatigue was significantly dependant on depression meas-
ured by HADS-D (p<0.001) and VAS pain (p<0.001).
Conclusion: Fatigue is highly prevalent in SLE patients. This study identi-
fied a number of factors that are significantly related to fatigue; of these
it is most strongly dependent on depression and pain. This suggests that
the aetiology of fatigue in SLE is multi-factorial and that in SLE patients
reporting fatigue, the underlying cause needs to be identified and treated.
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Background: Evidence of an increased risk to develop haematological
malignancy, and especially non-Hodgkin’s lymphoma (NHL) in autoimmune
diseases, has been gathered since the 1970s. In the last decade studies
from SLE cohorts have consistently shown a markedly increased risk of
NHL.
Objectives: To analyze clinical and disease characteristics in SLE
patients who developed a lymphoma during follow-up, as well as to
define characteristics of the lymphoma and its evolution.
Methods: Retrospective observational, longitudinal study conducted in a
tertiary hospital. Medical records of 362 patients with 4 SLICC classifi-
cation criteria of SLE were reviewed, including those with lymphoma diag-
nosis. Demographic and clinical data, comorbidities, SLE manifestations
and therapy, data related to lymphoma and outcome were collected.
Descriptive statistic analysis with measures of central tendency and meas-
ures of variability was performed.
Results: Of the 362 SLE patients, 9 (2.5%) were diagnosed of lym-
phoma, of which 100% female. Mean age at SLE diagnosis was 34 y.o
(SD 11) and average duration from SLE diagnosis to lymphoma was 17
years (SD 14). 7 patients were caucasian and 2 hispanic. Observed
comorbidities were hypertension (6 pt, 67%), diabetes (2 pt, 22%), dyslipi-
demia (3 pt, 33%), HBV infection (1 pt, 11%) and active smoking (6 pt).
No malignancy history was detected. Most frequent SLE features were
haematological (9 pt, 100%), joint (5 pt, 56%) and skin (5 pt) involve-
ment. The serious ones were: 3 patients with haemolytic anaemia (1 of
them, platelets <20000), 2 epilepsia (1 of them with CNS vasculitis), 1
glomerulonephritis, 1 pulmonary hypertension and 1 hemophagocytic syn-
drome. Only 1 patient had overlap with Sjögren’s syndrome. At the time
of lymphoma diagnosis, 7 patients were on steroids, 4 on immunosup-
pressants (2 mycophenolate, 1 azathioprine and 1 rituximab) and 3 on
antimalarials (Table 1). Mean age at lymphoma diagnosis was 51 y.o
(SD 10). 5 patients (56%) had diffuse large B-cell lymphoma (DLBCL), 1
had NHL, 1 had Hodgkin’s lymphoma, 1 had mantle B-cell lymphoma
and 1 had MALT lymphoma. Only 1 patient, of 4 with available data,
had EBV positive in the tissue. 7 patients (78%) received chemotherapy
and 2 patients completed treatment with autologous peripheral stem-cell
transplantation. Three patients died, 2 due to lymphoma and one due to
other causes (severe flaccid paralysis, Miller Fisher syndrome). Overall
survival after lymphoma diagnosis was 8 years (SD 6).
Conclusion: In our patients, unlike that reported in the literature, lym-
phoma diagnosis was in SLE with longer duration of the disease, and all
cases were female. Most frequent subtype was NHL, and all patients
had previous haematological manifestations. Regarding previous SLE treat-
ments, 5 patients had been exposed to immunosuppressants.
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